Silvia NOVELLO

Professor

Università degli Studi di Torino

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Silvia Novello is a faculty member at the Università degli Studi di Torino in Italy. Her research focuses on lung cancer treatment, including the effects of immunotherapies and the role of genetic mutations in therapy responses. Recent publications highlight her work on anti-PD-(L)1 monoclonal antibodies, c-Met inhibitors, and the impact of armed conflict on cancer patients. Professor Novello is committed to advancing the understanding and treatment of non-small cell lung cancer through clinical trials and systematic reviews.

Articles (11)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (7)

Suresh Ramalingam

Professor, Director of Medical Oncology

Emory University

UNITED STATES

View details

Marina Garassino

Università degli Studi di Torino

ITALY

View details

Christian Rolfo

Professor, Assoc. Director of Clinical Research

Mount Sinai Hospital

UNITED STATES

View details

Dariusz Kowalski

MD, PhD, Prof

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

Giovanni Farinea

University of Turin

ITALY

View details

JULIEN MAZIERES

PROFESSOR

FRANCE

View details

Jacek Jassem

professor

Medical University of Gdansk

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Silvia NOVELLO

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

The effects of race on anti-PD-(L)1 monoclonal antibodies in non-small cell lung cancer: A systematic literature review and meta-analysis

HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI

Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations

Lung cancer in Europe: The way forward

The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon

Repositioning PARP inhibitors in the treatment of thoracic malignancies

Pericarditis during chemoimmunotherapy for non–small cell lung cancer: an adverse event to prevent and recognise

Collaborators (7)

Suresh Ramalingam

Marina Garassino

Christian Rolfo

Dariusz Kowalski

Giovanni Farinea

JULIEN MAZIERES

Jacek Jassem

Make your next move.